Castuner

Oncotarget

Oncotarget Podcast

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Сайт подкаста

Слушайте в своём приложении

Эпизоды

500 эпизодов

  1. Multi-Kinase Inhibitor Temporarily Delays Ewing Sarcoma Growth in Preclinical Model 11:58
  2. Coagulation-Related Genes and Tumor Location Linked to Lung Cancer Survival 10:15
  3. International Tumor Board Explores Personalized Treatment Strategies for Colon Cancer Without Measurable Disease 9:27
  4. International Tumor Board Explores Personalized Treatment Options for Glioblastoma With MDM2 and EGFR Amplifications 8:42
  5. Molecular Tumor Board Maps Precision Treatment Options for a Woman With Multiple Primary Cancers 17:02
  6. Pan-Cancer Analysis Identifies Buckwheat-Derived Compound as Potential AKT1 Drug-Design Candidate 8:26
  7. Epigenetic Silencing of TRAIL-R2 Is Linked to Aggressive Features in Breast Cancer 14:04
  8. Gut Microbiome Emerges as a Potential Partner in Precision Cancer Therapy 6:09
  9. DHHC3 Helps Melanoma Tumors Evade Antitumor Immunity 11:16
  10. Commentary Calls for Consistent Evaluation of Potential Links Between COVID-19, Vaccination and Cancer 2:02
  11. Restoring MHC-I Expression Could Strengthen Immune Responses Against CNS Cancers 6:42
  12. Therapeutic HPV Vaccine PepCan Tested for Preventing Head and Neck Cancer Recurrence 12:46
  13. Oncotarget Supports WIN 2026 Symposium Advancing Precision Oncology 2:33
  14. Tumor-Derived Extracellular Vesicles Show Promise for Earlier Detection of Metastatic Risk 6:00
  15. Tumor-Infiltrating Lymphocyte Therapy Offers a Promising Approach for Treating Solid Tumors 4:20
  16. KRAS G12C Mutation Identified as a Rare Potential Target in Genitourinary Cancers 4:29
  17. New Analysis Challenges Methods Used to Measure Residual DNA in mRNA Vaccines 6:37
  18. Experimental Compounds Push Cancer-Promoting Pathways Into Overdrive in Pancreatic Cancer Cells 15:53
  19. Trk and IGF1R-Related Signaling Linked to Delayed Ewing Sarcoma Growth 6:50
  20. CTHRC1 in the Tumor Microenvironment Drives Colorectal Cancer Growth in Mouse Study 9:03
  21. Artificial Intelligence Could Transform Nutrition Care for Cancer Patients 8:41
  22. Molecular Tumor Board Explores Personalized Treatment Strategies for Patient with Multiple Cancers 5:53
  23. Rare Genetic Combination in Gastrointestinal Tumor Offers New Insights Into Precision Cancer Care 7:25
  24. Rare Benign Kidney Tumor Case Highlights Value of Biopsy and Minimally Invasive Treatment 4:55
  25. Targeted Therapies Coincided With Dramatic Decline in Multiple Myeloma Mortality in the US 6:17
  26. TRAIL-R2 Silencing Linked to More Aggressive Breast Cancer 4:28
  27. Protein Linked to Melanoma Growth May Suppress the Body’s Natural Anti-Tumor Immune Response 4:33
  28. PDX1 May Link Metabolic Dysfunction to Prostate Cancer Progression 8:07
  29. HPV Vaccine Shows Safety but Uncertain Benefit in Preventing Head & Neck Cancer Recurrence 4:36
  30. Experimental Compounds Trigger Cancer Cell Death in KRAS-Driven Pancreatic Cancer 5:14
  31. Cancer Care Often Overlooked in Humanitarian Crises 4:24
  32. Protein in Tumor Microenvironment Found to Promote Colorectal Cancer Growth and Immune Evasion 4:17
  33. Immune Checkpoint Inhibitors May Improve Outcomes in High-Risk Solid Tumors 4:13
  34. Rare Laryngeal Leiomyosarcoma Successfully Treated with Surgery and Adjuvant Chemotherapy 4:26
  35. Agentic AI Systems May Transform Nutritional Care in Oncology 4:02
  36. Rare Dual-Mutation GIST Responds to Targeted Therapy, Challenging Established Tumor Biology 4:07
  37. Mapping the Hidden Structure of Glioma Research: What Are We Missing? 5:03
  38. Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the U.S. 3:23
  39. SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing 5:40
  40. Epigenetic Dysregulation of PDX1 Drives Prostate Cancer Progression 2:40
  41. Cancer Care in Conflict Zones Remains Critically Neglected 2:04
  42. Oncotarget Editorial Highlights Advances in Scientific Integrity and Publishing Transparency 1:57
  43. CREB5: A Master Regulator of Stem Cell-Like Programs in Prostate Cancer Progression 10:49
  44. Adjuvant PD-1/PD-L1 Inhibitors Show Efficacy but Highlight Safety Considerations in Solid Cancers 2:49
  45. Bibliometric Mapping Reveals the Evolution of Glioma Classification Research 2:28
  46. The SCD1 Inhibitor Aramchol, Regorafenib, and Metformin Combine to Kill Uveal Melanoma Cells 2:12
  47. Predicting Colorectal Cancer Survival: How Machine Learning Combines Clinical and Biological Clues 8:36
  48. CREB5 Linked to Stem Cell-Like Programs That Promote Prostate Cancer Progression 2:52
  49. Impact Journals to Participate at AACR Annual Meeting 2026 in San Diego 1:40
  50. CAR-T Cell Therapy: A Revolutionary Approach to Cancer Treatment 6:44